Targeting MEK for the Treatment of Non Small-Cell Lung Cancer

Por Goldman, Jonathan W., Garon, Edward B.
Publicado em 2012

Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management

Por Goldman, Jonathan W., Mendenhall, Melody A., Rettinger, Sarah R.
Publicado no Oncologist (2016)

KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment

Por Cummings, Amy Lauren, Santoso, Kate M., Goldman, Jonathan W.
Publicado no Transl Lung Cancer Res (2019)

Extended Progression-Free Survival in Two Patients With Alveolar Soft Part Sarcoma Exposed to Tivantinib

Por Goldberg, John M., Gavcovich, Tara, Saigal, Gaurav, Goldman, Jonathan W., Rosen, Lee S.
Publicado no J Clin Oncol (2014)

Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management

Por Shen, John, Chang, Jason, Mendenhall, Melody, Cherry, Grace, Goldman, Jonathan W., Kulkarni, Rajan P.
Publicado no Ther Adv Med Oncol (2018)

PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin – case report

Por Goldman, Jonathan W., Abdalla, Basmah, Mendenhall, Melody A., Sisk, Anthony, Hunt, Jaime, Danovitch, Gabriel M., Lum, Erik L.
Publicado no BMC Nephrol (2018)

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

Por Shaverdian, Narek, Lisberg, Aaron E, Bornazyan, Krikor, Veruttipong, Darlene, Goldman, Jonathan W, Formenti, Silvia C, Garon, Edward B, Lee, Percy
Publicado no Lancet Oncol (2017)

Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung C...

Por Gaut, Daria, Sim, Myung Shin, Yue, Yuguang, Wolf, Brian R., Abarca, Phillip A., Carroll, James M., Goldman, Jonathan W., Garon, Edward B.
Publicado no Clin Lung Cancer (2017)

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

Por Bendell, Johanna C., Rosen, Lee S., Mayer, Robert J., Goldman, Jonathan W., Infante, Jeffrey R., Benedetti, Fabio, Lin, Donghu, Mizuguchi, Hirokazu, Zergebel, Christopher, Patel, Manish R.
Publicado no Cancer Chemother Pharmacol (2015)

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors

Por Falchook, Gerald S., Zhou, Xiaofei, Venkatakrishnan, Karthik, Kurzrock, Razelle, Mahalingam, Devalingam, Goldman, Jonathan W., Jung, JungAh, Ullmann, Claudio Dansky, Milch, Catherine, Rosen, Lee S., Sarantopoulos, John
Publicado no Drugs R D (2015)

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

Por Bendell, Johanna C., Rosen, Lee S., Mayer, Robert J., Goldman, Jonathan W., Infante, Jeffrey R., Benedetti, Fabio, Lin, Donghu, Mizuguchi, Hirokazu, Zergebel, Christopher, Patel, Manish R.
Publicado no Cancer Chemother Pharmacol (2015)

Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Ca...

Por Goldman, Jonathan W., Waterhouse, David M., George, Ben, O'Dwyer, Peter J., Bhore, Rafia, Banerjee, Sibabrata, Lyons, Larry, Louis, Chrystal U., Ong, Teng Jin, Kelly, Karen
Publicado no Front Oncol (2019)

Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer

Por Dhar, Manjima, Wong, Jessica, Che, James, Matsumoto, Melissa, Grogan, Tristan, Elashoff, David, Garon, Edward B., Goldman, Jonathan W., Sollier Christen, Elodie, Di Carlo, Dino, Kulkarni, Rajan P.
Publicado no Sci Rep (2018)

A longitudinal investigation of internalized stigma, constrained disclosure, and quality of life across 12 weeks in lung cancer patients on active oncologic treatment

Por Williamson, Timothy J., Choi, Alyssa K., Kim, Julie C., Garon, Edward B., Shapiro, Jenessa R., Irwin, Michael R., Goldman, Jonathan W., Bornyazan, Krikor, Carroll, James M., Stanton, Annette L.
Publicado no J Thorac Oncol (2018)

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid ma...

Por Goldman, Jonathan W, Raju, Robert N, Gordon, Gregory A, El-Hariry, Iman, Teofilivici, Florentina, Vukovic, Vojo M, Bradley, Robert, Karol, Michael D, Chen, Yu, Guo, Wei, Inoue, Takayo, Rosen, Lee S
Publicado em 2013

Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand–1 Expression for Immunotherapy in Non–Small Cell Lung Cancer

Por Tsai, Emily B., Pomykala, Kelsey, Ruchalski, Kathleen, Genshaft, Scott, Abtin, Fereidoun, Gutierrez, Antonio, Kim, Hyun J., Li, Alice, Adame, Carlos, Jalalian, Ashkan, Wolf, Brian, Garon, Edward B., Goldman, Jonathan W., Suh, Robert
Publicado no Radiology (2018)

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors

Por Rosen, Lee S., LoRusso, Patricia, Ma, Wen Wee, Goldman, Jonathan W., Weise, Amy, Colevas, A. Dimitrios, Adjei, Alex, Yazji, Salim, Shen, Angela, Johnston, Stuart, Hsieh, Hsin-Ju, Chan, Iris T., Sikic, Branimir I.
Publicado no Invest New Drugs (2016)

High efficiency vortex trapping of circulating tumor cells

Por Dhar, Manjima, Wong, Jessica, Karimi, Armin, Che, James, Renier, Corinne, Matsumoto, Melissa, Triboulet, Melanie, Garon, Edward B., Goldman, Jonathan W., Rettig, Matthew B., Jeffrey, Stefanie S., Kulkarni, Rajan P., Sollier, Elodie, Di Carlo, Dino
Publicado no Biomicrofluidics (2015)

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer

Por Goldman, Jonathan W., Rosen, Lee S., Tolcher, Anthony W., Papadopoulos, Kyriakos, Beeram, Muralidhar, Shi, Peipei, Pitou, Celine, Bell, Robert, Kulanthaivel, Palaniappan, Zhang, Xuekui, Fink, Aaron, Chan, Edward M., Shahir, Ashwin, Farrington, Daphne, Patnaik, Amita
Publicado no Invest New Drugs (2017)

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

Por Vadhan-Raj, Saroj, Abonour, Rafat, Goldman, Jonathan W., Smith, David A., Slapak, Christopher A., Ilaria, Robert L., Tiu, Ramon V., Wang, Xuejing, Callies, Sophie, Cox, Joanne, Tuttle, Jay L., Lau, Yiu-Keung, Roeland, Eric J.
Publicado no J Hematol Oncol (2017)